Search - tctmd.com

Displaying 681 - 700 of 1004

Sort: Relevancy | Date

News Industry News

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

October 26, 2012

Presentation TCT 2012

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Presenter: Antonio Colombo

October 26, 2012

News Industry News

Low Responsiveness to Clopidogrel Predicts Stent Thrombosis, Heart Attack; but is Not Directly Linked to Death

October 25, 2012

News Industry News

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

October 25, 2012

News Industry News

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

October 25, 2012

Presentation TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Presenter: Dean Kereiakes

October 25, 2012

News Conference News TCT 2012

Positive Results Seen with Angioplasty for Critical Hand Ischemia

October 25, 2012

News Conference News TCT 2012

Paclitaxel-Eluting Balloon Results in High Patency Rate at 1 Year in Below-the-Knee Lesions

October 25, 2012

Presentation TCT 2012

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Presenter: Hyeon-Cheol Gwon

October 24, 2012

News Industry News

Second Generation Drug-Eluting Stents are Safe and Effective in Treatment of Left Main Coronary Artery Disease

October 24, 2012

News Industry News

Reported at TCT 2012: InspireMD MGuard Stent Meets Primary Endpoint of MASTER Trial, Significantly Improving Prospects of Heart Attack Survival

October 24, 2012

News Industry News

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

October 24, 2012

News Industry News

Mesh-Covered Stent Improves Restoration of Blood Flow in Heart Attack Patients Undergoing Angioplasty

October 24, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

October 24, 2012

News Industry News

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

October 24, 2012

News Conference News TCT 2012

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

October 24, 2012

Presentation TCT 2012

TCT-70. Comparison of Efficacy and Safety Between Sirolimus, Paclitaxel, Everolimus-eluting Stent and SeQuent™ Please, a Drug-eluting Balloon on the Outcome of Patients with...

Presenter: Sunao Nakamura

October 23, 2012

Presentation TCT 2012

TCT-69. PEPCAD-DES: A Randomized, Multicenter, Single Blinded Trial Comparing Paclitaxel Coated Balloon Angioplasty with Plain Balloon Angioplasty in Drug-eluting-stent...

Presenter: Harald Rittger

October 23, 2012

Presentation TCT 2012

TCT-75. Lumen Enlargement of the Coronary Segments Located Distal to Chronic Total Occlusions Successfully Treated with Drug-Eluting Stents at Follow-up

Presenter: Josep Gomez-Lara

October 23, 2012

Presentation TCT 2012

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Presenter: Ajay Kirtane

October 23, 2012

Advertisement

Study Finds Drug-Eluting Stents Exhibit Some Benefits Over Bare-Metal Stents In Patients Over 80, Though Both Demonstrate Clinical Benefit

Reflections on Coronary Stents: From Bare Metal to Drug-Eluting to Bioabsorbable: My Personal Delights and Dilemmas

Low Responsiveness to Clopidogrel Predicts Stent Thrombosis, Heart Attack; but is Not Directly Linked to Death

Elixir Medical Announces Enrollment Completion of the DESolve Nx Pivotal Trial for Fully Bioresorbable Coronary Scaffold System

8500+ Patient Trial Validates Association between High Platelet Reactivity and 1-Year Cardiovascular Outcomes at TCT 2012

When Is PCI Justified in Complex (Non-Left Main) Multivessel Disease with Current Drug-Eluting Stents?

Positive Results Seen with Angioplasty for Critical Hand Ischemia

Paclitaxel-Eluting Balloon Results in High Patency Rate at 1 Year in Below-the-Knee Lesions

"Six-Month Versus 12-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents: The Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting...

Second Generation Drug-Eluting Stents are Safe and Effective in Treatment of Left Main Coronary Artery Disease

Reported at TCT 2012: InspireMD MGuard Stent Meets Primary Endpoint of MASTER Trial, Significantly Improving Prospects of Heart Attack Survival

PROMUS Element™ and PROMUS Element™ Plus Receive CE Mark Approval for Labeling Update to Include Three-Month Dual Anti-Platelet Therapy

Mesh-Covered Stent Improves Restoration of Blood Flow in Heart Attack Patients Undergoing Angioplasty

Elixir Medical Corporation Announces Outstanding Three-Year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System

Elixir Medical Corporation Announces Outstanding Three-year Data from the EXCELLA II Randomized Clinical Trial for the CE Mark-Approved DESyne® System(2)

DEBATE-SFA Favors Predilatation with Drug-Eluting Balloon Before BMS

TCT-70. Comparison of Efficacy and Safety Between Sirolimus, Paclitaxel, Everolimus-eluting Stent and SeQuent™ Please, a Drug-eluting Balloon on the Outcome of Patients with...

TCT-69. PEPCAD-DES: A Randomized, Multicenter, Single Blinded Trial Comparing Paclitaxel Coated Balloon Angioplasty with Plain Balloon Angioplasty in Drug-eluting-stent...

TCT-75. Lumen Enlargement of the Coronary Segments Located Distal to Chronic Total Occlusions Successfully Treated with Drug-Eluting Stents at Follow-up

Bare Metal vs. Drug-Eluting Stents: Mechanisms of Action and Comparative Effectiveness and Safety

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content